Dover Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-4,828
Closed -$262K 128
2024
Q1
$262K Buy
+4,828
New +$246K 0.18% 103
2023
Q2
Sell
-3,005
Closed -$208K 105
2023
Q1
$208K Buy
3,005
+175
+6% +$12.3K 0.2% 93
2022
Q4
$204K Buy
+2,830
New +$213K 0.22% 93

Other funds holding BMY

Dover Advisors's BMY Position: Q2 2024 in Review

Dover Advisors sold out of Bristol-Myers Squibb (BMY) in Q2 2024, closing a stake of 4,828 shares — an estimated $262K sold.

Dover Advisors first reported a position in BMY in Q4 2022 and held it in 3 quarters. The position peaked at $262K in Q1 2024. 2,152 funds tracked by Wall St. Rank hold BMY as of Q2 2024.

  • Dover Advisors reported no remaining Bristol-Myers Squibb position as of Q2 2024 after selling out during the quarter.
  • Dover Advisors sold 4,828 Bristol-Myers Squibb shares in Q2 2024, an estimated $262K.
  • Dover Advisors first reported a position in Bristol-Myers Squibb in Q4 2022 and held it in 3 quarters.
  • Dover Advisors's Bristol-Myers Squibb position peaked at $262K in Q1 2024.
  • 2,152 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2024.

Based on Dover Advisors's 13F filing for Q2 2024, filed 31 Jul 2024.